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Introduction
There is limited literature on the appropriateness of viral load (VL) monitoring and management of
detectable VL in public health settings in rural South Africa.
Methods
We analysed data captured in the electronic patient register from HIV-positive patients ≥ 15 years
old initiating antiretroviral therapy (ART) in 17 public sector clinics in rural KwaZulu-Natal,
during 2010–2016. We estimated the completion rate for VL monitoring at 6, 12, and 24 months.
We described the cascade of care for those with any VL measurement ≥ 1000 HIV-1 RNA copies/
mL after ≥ 20 weeks on ART, including the following proportions: (1) repeat VL within 6 months;
(2) re-suppressed; (3) switched to second-line regimen.
Results
There were 29 384 individuals who initiated ART during the period [69% female, median age
31 years (interquartile range 25–39)]. Of those in care at 6, 12, and 24 months, 40.7% (9861/24 199),
34% (7765/22 807), and 25.5% (4334/16 965) had a VL test at each recommended time-point,
respectively. The VL results were documented at all recommended time-points for 12% (2730/22 807)
and 6.2% (1054/16 965) of ART-treated patients for 12 and 24 months, respectively. Only 391
(18.3%) of 2135 individuals with VL ≥ 1000 copies/mL on first-line ART had a repeat VL
documenting re-suppression or were appropriately changed to second-line with persistent failure.
Completion of the treatment failure cascade occurred a median of 338 days after failure was detected.
Conclusion
We found suboptimal VL monitoring and poor responses to virologic failure in public-sector ART
clinics in rural South Arica. Implications include increased likelihood of morbidity and
transmission of drug-resistant HIV.
Keywords: antiretroviral therapy, HIV drug resistance, South Africa, viral load monitoring,
virological failure
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Introduction
UNAIDS estimates that to end HIV/AIDS as a public
health threat by 2030, 95% of people living with HIV
must be diagnosed, 95% of those diagnosed need to be
taking antiretroviral therapy (ART), and 95% of those
must achieve long-term virologic suppression [1]. To
ascertain this third target, HIV treatment programmes in
sub-Saharan Africa (SSA) will need to scale up viral load
(VL) monitoring, and to institute prompt and appropriate
management strategies for those failing therapy.
According to WHO guidelines, patients should receive
VL monitoring at months 6 and 12 after ART initiation,
and then annually thereafter. Those with a VL ≥ 1000
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SHORT COMMUNICATION
HIV-1 RNA copies/mL should be retested after 3–
6 months of adherence counselling support, and then
either retained on first-line therapy if re-suppressed or
switched to second-line therapy if VL ≥ 1000 copies/mL
[2]. Yet, despite the rapid and successful scaling-up of VL
monitoring, little is known about how these VL guidelines
are being used in clinical decision-making in public ART
programmes in SSA. With increases in drug resistance in
the region [3-5], there is concern over an epidemic of
ART failure compromising already challenging efforts to
combat HIV/AIDS as a public health threat.
We observed HIV-positive individuals after ART initia-
tion in a programmatic clinical cohort in KwaZulu-Natal,
to determine whether guidelines about management of
virologic failure are being implemented. We hypothesized
that poor adherence to VL monitoring guidelines has
resulted in poor identification of treatment failure and
prolonged duration on failing first-line regimens.
Methods
Setting, study design and population
This study was conducted in the Hlabisa sub-district as
part of the Africa Health Research Institute (AHRI) demo-
graphic surveillance and clinical population cohort [6].
All HIV-positive individuals who initiate ART at any of
the 17 area-based public sector clinics have had clinical
data prospectively recorded through the Three Interlinked
Electronic Register (TIER.net) since 2013. Prior to this
period, data were back-captured in TIER.net. All data
were linked to the AHRI longitudinal population cohort.
At the time of linkage, visits with implausible dates (VL
test dates, date of ART initiation) and duplicate visits
resulting from back capturing when a patient is trans-
ferred from one clinic to another were dropped. ART regi-
men codes were also examined for systematic errors. In
this analysis, we included all individuals during 2010–
2016 in care at a public-sector HIV clinic with a recorded
ART initiation date.
Viral load monitoring
Since 2010, South African HIV treatment guidelines have
recommended VL monitoring in all HIV-positive individ-
uals at 6 and 12 months after initiating ART, and 12-
monthly thereafter if virally suppressed [7]. HIV-positive
individuals attending the healthcare clinics undergo
venepuncture by the clinic staff with plasma samples
transported to the Hlabisa District hospital daily, where
HIV-1 VL is done (m2000 RealTime System; Abbott
Molecular, Abbott Park, Illinois, U.S.A). The results are
delivered to the clinics during sample pick-up and are
manually entered by clinic clerks into TIER.Net. The
paper results are subsequently filed in patients’ clinical
charts. Patients who have an HIV VL ≥ 1000 copies/mL
after at least 6 months on ART are recommended to
receive adherence counselling followed by a repeat VL 2–
3 months after the initial detection of elevated VL. If the
repeat HIV VL is ≥ 1000 copies/mL, individuals are meant
to be switched to second-line ART. Those with VL < 1000
copies/mL remain on first-line therapy.
Statistical methods
Data were extracted from Tier.Net, containing HIV
records for patients on ART in the sub-district and anal-
ysed using Stata version 14 (College Station, TX, USA).
We first estimated the completion rate for VL monitoring
at 6, 12, and 24 months, by using VL measurements
which fall within the 6-month (≥ 5 and ≤ 9 months), 12-
month (> 9 and ≤ 15 months) and 24-month (> 21 and
≤ 27 months) windows after ART initiation, respectively.
The denominators for each of these time-points were peo-
ple who had started ART and were in care at the evalu-
ated time point, although there might have been
interruptions outside of the time periods evaluated. As a
sensitivity analysis, we examined VL monitoring
restricted to individuals who remained continuously in
care over each time period.
We estimated optimal VL monitoring defined as com-
pleting both 6- and 12-month VL for those on ART for a
minimum of 15 months and at 6, 12, and 24 months for
those on ART for a minimum of 27 months.
We described the cascade of care for all individuals with
a VL measurement ≥ 1000 copies/mL after at least
5 months on ART, including the proportion with a repeat
VL within 6 months (allow a window of 10–30 weeks after
VL ≥ 1000 copies/mL), the proportion who re-suppressed,
and the proportion who changed to a second-line regimen
if a repeat VL remained ≥ 1000 copies/mL. For the cascade
of care analysis, we restricted our analysis to the first epi-
sode of virologic failure for each individual in the dataset.
We examined factors associated with successful manage-
ment of the first-line cascade using logistic regression,
among all individuals with virologic failure. Successful
management was defined as having a repeat VL test within
6 months, and either VL < 1000 copies/mL on repeat test-
ing or switch to an appropriate second-line therapy.
Ethics
Ethical approval for the AHRI Population Intervention
Platform Study and linkage to government ART records
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(TIER.net) was granted by the Biomedical Research Ethics
Committee of the University of KwaZulu-Natal, SA
(BE290/16).
Results
Between January 2010 and December 2016, 29 384 HIV-
positive individuals initiated ART in the public sector in
our study catchment area (Table 1). The median age was
31 years [interquartile range (IQR): 26–39] and 69.9%
were female. Of those on ART for 6, 12 and 24 months,
we found that 40.7% (9861/24 199), 34% (7765/22 807),
and 25.5% (4334/16 965) had a VL test documented at
each recommended time-point, respectively.
Optimal VL monitoring including all recommended
time-points for those on ART for 12 and 24 months was
documented for 12% (2730/22 807/22 730) and 6.2%
(1054/16 965), respectively. The proportion of individuals
with month-24 VL monitoring recorded declined from
39.0% in 2010 to 12.5% in 2015. A similar decline was
seen when optimal monitoring at 24 months was evalu-
ated, going from 10.1% to 2.2%. Viral monitoring varied
by clinic, with optimal monitoring at 12 months ranging
from 2.7% to 33.9%, and that at 24 months ranging from
0.5% to 17.9%. (Table S1). The results of sensitivity anal-
ysis restricted to those continuously in care were similar
to the main analysis (Table S2). Over the study period,
77.6% and 70.8% remained in care at 12 and 24 months
after ART initiation, respectively (Table S3). Of the
29 384 individuals who started ART, 19 582 (66.6%) had
at least one VL measurement recorded at any point
> 20 weeks after starting ART. Ten per cent (2135) had at
least one VL ≥ 1000 copies/mL (Table S4); 64.5% were
female, and median (IQR) time to failure was 469 (264–
849) days. Of those with VL ≥ 1000 copies/mL, 658
(30.8%) had a repeat VL recorded within 6 months, and
391 (18.3%) achieved successful management of virologic
failure with either a repeat VL < 1000 copies/mL or
appropriate change to second-line therapy (Fig. 1). For
the 141 individuals who switched to second-line therapy,
the median (IQR) time to regimen change was 338 days
(135–713) after their first elevated VL measurement. In
the multivariable analysis, successful management was
strongly associated with increasing duration on ART and
weakly associated with being female [1.23, 95% confi-
dence interval (CI): 0.95–1.60, P = 0.11] and under
25 years of age (1.34, 95% CI: 0.99–1.83, P = 0.14)
(Table S5).
Discussion
In a representative population-based longitudinal clinical
cohort attending public sector primary care clinics in rural
South Africa, we found significant deficits in VL monitor-
ing and delayed or absent responses to virologic failure.
Indeed, less than one in five individuals in this program-
matic cohort were confirmed to have virologic re-suppres-
sion or change to second-line therapy after virologic
failure, and those that did change therapy did so a median
of 1 year after virologic failure. Such delays are likely to
Table 1 Proportion of individuals aged ≥ 15 years with viral load (VL) monitoring, and with optimal monitoring, during first 12 and









n with VL at
6 months/
N on ART† (%)
n with VL at
12 months/
N on ART‡ (%)
n with VL at
24 months/









2010 3177 33 (27–41) 67.5 1234/2495 (49.5%) 869/2354 (36.9%) 839/2150 (39.0%) 361 (15.3%) 217 (10.1%)
2011 3543 34 (27–41) 69.4 1544/2961 (52.1%) 1021/2823 (36.2%) 764/2597 (29.4%) 381 (13.5%) 153 (5.9%)
2012 4040 33 (27–41) 66.7 1495/3406 (43.9%) 977/3235 (30.2%) 865/2993 (28.9%) 328 (10.1%) 146 (4.9%)
2013 3642 30 (25–38) 71.1 907/2897 (31.3%) 757/2741 (27.6%) 750/2523 (29.7%) 207 (7.6%) 101 (4.0%)
2014 3988 29 (24–37) 73.3 793/3231 (24.5%) 1017/3045 (33.4%) 619/2740 (22.6%) 252 (8.3%) 87 (3.2%)
2015 5556 31 (25–38) 70.6 2035/4695 (43.3%) 1391/4428 (31.4%) 497/3962 (12.5%) 519 (11.7%) 88 (2.2%)
2016 5438 31 (25–38) 69.8 1853/4514 (41.1%) 1733/4181 (41.4%) – 682 (16.3%) –
Total 29 384 31 (26–39) 69.9 9861/24 199 (40.7%) 7765/22 807 (34.0%) 4334/16 965 (25.5%) 2730 (12.0%) 1054 (6.2%)
†
Viral load measurement done between > 20 weeks and 9 months after starting ART. Denominator refers to individuals who have been on ART for at
least 9 months.
‡
Viral load measurement done between > 9 and 15 months after starting ART. Denominator refers to individuals who have been on ART for at least
15 months.
§
Viral load measurement done between > 21 and 27 months after starting ART. Denominator refers to individuals who have been on ART for at least
27 months.
¶
Optimal monitoring during first 12 months is defined as a viral load measurement at 6 and 12 months after ART initiation, using the windows in
footnotes † is > 20 weeks and 9 months and ‡ is > 9 months and 15 months. Denominator refers to individuals who have been on ART at least
15 months.
#
Optimal monitoring during the first 24m is defined as a viral load measurement at 6m, 12m and 24m after ART initiation, using windows in footnotes
† is > 20 weeks and 9 months, ‡ is > 9 months and 15 months and § is > 21 months and 27 months. Denominator is individuals who have been on
ART at least 27 months.
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have significant deleterious individual and public health
impacts through effects on patient morbidity, accumula-
tion of drug resistance, and persistent risk of HIV trans-
mission. Furthermore, suboptimal VL monitoring could
lead to inaccurate decisions by policymakers on pro-
gramme effectiveness and needs for second-line ART.
There are many potential reasons for the poor VL mon-
itoring observed in this treatment programme: patients
not being aware of or empowered to request recom-
mended blood tests, facility staff not having training, suf-
ficient time or resources to conduct blood tests when due,
failure of results to reach clinics from the laboratory or
failure to capture results on TIER.Net. It is a limitation of
this study that we did not review clinical records as our
ethics permission did not cover this, hence we are uncer-
tain which of these factors might account for this poor
VL monitoring. The decline in optimal VL monitoring
over time was most apparent for the 24 month time-
point; by contrast, there appeared to be some improve-
ment in more recent years in optimal monitoring at
12 months. Hence, we speculate that this could be due to
prioritization of monitoring of patients with advanced
disease as they start care over the first few months of
treatment and a relaxation in monitoring frequency as
patients become more established on ART, especially in
the context of high patient burden and staff shortages. If
VL data in the TIER.net database are not missing at ran-
dom, such that they are more likely to be missing among
those with a suppressed VL, it would falsely bias our
findings to suggest worse VL suppression rates. However,
TIER.net is the system most often used for regional and
national HIV reporting, so our data would be similar to
what would be expected for programmatic reporting by
the Department of Health. A study in Khayelitsha, South
Africa, comparing laboratory VL data with clinic level VL
database over a 12-month period reported a higher VL
completion (84%) with laboratory records but with only
55% captured in clinic database [8]. However, a South
African study including data from four provinces exam-
ined a random sample of patients’ clinical records to
ascertain the reason for missing VL and concluded that
VL were missing on TIER.Net because they were not done
[9]. Another clinical chart audit from 11 clinics in Kwa-
Zulu-Natal demonstrated that only 42%, 32% and 26% of
adult patients underwent VL testing at 6 months, 1 year
and 2 years after ART initiation, respectively, which is
similar to our findings [10]. These studies did not assess
the use of VL results for clinical decision-making.
But perhaps more concerning than suboptimal VL
monitoring is the incredibly low response to detectable
VL we observed. Our findings are similar to a Mozambi-
can study which also reported a poor cascade of care in
response to virologic failure: an initial VL test occurred
on time in only 40% (17 236) of individuals, 18% of
whom had an elevated first VL, and 35% of whom had
an appropriate repeat. Amongst these 1095 with a fol-
low-up VL, 62% had virological failure. Of those, only a
third started second-line ART [11]. An assessment of the
public ART programme in Lesotho following the roll-out
of VL monitoring in one district reported a similar poor
health system response to detectable VL [12]. However,
better management of detectable VL was reported in
Fig. 1 Cascade of care after detection of virological failure. VL, viral load.
© 2020 The Authors.
HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association
HIV Medicine (2020)
4 CC Iwuji et al.
another Lesotho study within the context of a prospective
study [13] as well as in Swaziland [14]. A South African
modelling study investigated the reason for the high rates
of nonnucleoside reverse transcriptase inhibitor (NNRTI)
resistance in South Africa. The model was able to repro-
duce the time trends of HIV in South Africa from 2005 to
2016 and appropriately captured the dynamics of the
spread of NNRTI resistance. The model demonstrated that
the rapid scaling-up of ART and inadequate switching to
second-line ART were the key drivers of the spread of
NNRTI resistance in South Africa [15].
These data reinforce the urgent priority for ART care
programmes across the region to identify strategies to
ensure virologic failure is appropriately managed. Some
proposed strategies include task-shifting to allow nurses
to change individuals to second-line therapy with physi-
cian approval [16], immediate change to second-line
therapy after a first episode of virologic failure, use of
point-of-care HIV VL testing to support immediate deci-
sions by front-line clinic staff [17], or incorporation of
resistance testing to better differentiate between adher-
ence and resistance-based failure and encourage clini-
cians to respond appropriately [18]. The early detection
and prompt management of virological failure will be a
critical step towards achieving UNAIDS 95-95-95 targets
by 2030 [1].
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